

## Atezolizumab IMpower150

# PRELIMINARY SCORE

## CURATIVE



## NON-CURATIVE



# ADJUSTMENTS

## Quality of life



No improvement in QoL



## Serious and disabling adverse effects



## Other adjustments



## Atezolizumab IMpower150

# FINAL SCORE

## CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

## NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

## INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: In combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC)

Experimental Arm: Atezolizumab + Bevacizumab, paclitaxel and carboplatin

Control Arm: Bevacizumab, paclitaxel and carboplatin



